Assigment .Apa seven . All instructions attached.

Surname 1

Isairy Otano

Florida National University

Advanced Writing and Research

Professor: Amanda M Giust

January 14, 2024

Pain Management with Medical Marijuana

Medical marijuana for pain relief is a key area of medical research and practice. Alternative remedies have grown as communities struggle to manage chronic pain. According to a research, the worldwide medical marijuana industry is growing exponentially, reaching US$96.7 billion by 2033 (NASDAQ OMX's News Release Distribution Channel, 3). High adoption of medical marijuana, especially for chronic pain management, is driving this rise. Medical marijuana is beneficial because of its chemical constituents, notably THC and CBD from the Cannabis sativa or Cannabis indica plant. Chronic pain, epilepsy, multiple sclerosis, cancer, and psychological disorders have been treated using these substances. Changing regulatory settings, patient and healthcare professional acceptability, and new medical application research drive the global market. This study examines medicinal marijuana's significance in pain therapy, including its expanding acceptance, legislative changes, and opioid use effects.

Medical Marijuana Pain Management Benefits

Medical marijuana has been shown to relieve pain in scientific research and anecdotes. Cannabis and its derivatives help reduce neuropathic, inflammatory, and chronic pain like multiple sclerosis and arthritis, according to emerging research. "Cannabis for the Management of Pain: Balu et al. (5) Pain found cannabis reduced pain more than a placebo. Candeloids may modulate pain, as individuals who used cannabis for pain treatment needed less opioids.

Market Dynamics:

Medical marijuana industry growth is driven by numerous factors, including global regulatory changes. Marijuana legalization and decriminalization have increased worldwide as governments and regulatory agencies recognize its medical benefits. Legalization expands the market and raises public knowledge of medical marijuana as a valid treatment. The widening list of medical disorders for which marijuana can be prescribed has also helped grow the market. Chronic pain, epilepsy, multiple sclerosis, and cancer symptoms have been shown to benefit from marijuana treatment. Product innovation has resulted from large R&D investments due to this acknowledgment (Hall, 6). These inventions include marijuana-based oils, edibles, tinctures, and topicals for distinct patient preferences and medicinal needs. Rising chronic disease rates worldwide drive medical marijuana demand. Medical marijuana can supplement or replace medicines for long-term chronic disease management. This appeals to patients seeking natural or holistic treatments. The market's numerous product offers make medical marijuana accessible and appealing to more patients, boosting its growth and acceptability.

Challenges

However, medical marijuana faces hurdles. Multimarket enterprises struggle with regional regulatory differences. Variability in product availability, legal compliance, and regulatory policies can hinder medicinal marijuana's global progress. The plant's diversity makes quality and standardization of medical marijuana products difficult. Cannabis is a herb with chemical variations, unlike manufactured drugs. Variation in product potency and effectiveness makes it difficult to standardize dose and assure consistent therapeutic benefits for patients.

Social stigma against marijuana usage in several societies remains a barrier. Cannabis is commonly associated with recreational drug use, which has led to social rejection and lack of acceptability in some areas, despite its medicinal benefits. This stigma can effect patient use of medical marijuana and healthcare provider prescriptions. Cannabis' medical research is further hindered by its Schedule I status in several nations, such as the US (Cooper et al., 4). This classification limits research funds and prospects, slowing scientific progress and medicinal advances.

Sectoring the Market:

Product categories, indications, distribution channels, and geographies segment the market. Dried flower and extract products are sold at retail pharmacies and online for pain management and seizure treatment. After many states legalized medical cannabis, the U.S. medical marijuana market, one of the largest worldwide, evolved. Strong research, product innovation, and a strong supply network boost its growth. Due to changing regulations and growing acceptance of cannabis-based medicines, the market is likely to rise. Tilray, Aurora Cannabis, Canopy Growth Corporation, and others are strengthening their positions through collaborations, acquisitions, and product line extensions. Canopy Growth's acquisition of Supreme Cannabis Company and Tauriga Sciences' cannabis/CBD chewing gum production agreement demonstrate the market's volatility.

Legal and Moral Issues

Medical marijuana is still debated in many places. Ethical issues like equitable access, patient autonomy, and cannabis stigma also influence its usage in pain therapy. Rønne et al. (5) reviewed cannabis prescribing ethics, including the necessity to weigh benefits and dangers. The changing legal landscape necessitates consistent norms and recommendations for safe and effective use.

Conclusion

Medical marijuana pain management is a promising topic that is expanding quickly. Medical marijuana's expanding global industry due to changing rules, acceptance, and research shows its growing importance in healthcare. Studies sheds light on how medical cannabis certification affects opioid consumption, supporting its use in pain therapy. As the industry grows, more research and clinical trials are needed to understand medical marijuana's function in chronic pain therapy and its problems.

Works Cited

Balu, Alan, et al. “Medical Cannabis Certification Is Associated with Decreased Opiate Use in Patients with Chronic Pain: A Retrospective Cohort Study in Delaware.” Cureus, 7 Dec. 2021, https://doi.org/10.7759/cureus.20240.

Cooper, Ziva D, et al. “Challenges for Clinical Cannabis and Cannabinoid Research in the United States.” JNCI Monographs, vol. 2021, no. 58, 27 Nov. 2021, pp. 114–122, https://doi.org/10.1093/jncimonographs/lgab009.

Hall, Wayne. “The Costs and Benefits of Cannabis Control Policies.” Dialogues in Clinical Neuroscience, vol. 22, no. 3, Sept. 2020, pp. 281–287, www.ncbi.nlm.nih.gov/pmc/articles/PMC7605025/, https://doi.org/10.31887/dcns.2020.22.3/whall.

NASDAQ OMX’s News Release Distribution Channel. “Medical Marijuana Market Blooms with a Projected Value of US$96.7 Billion by 2033, Persistence Market Research.” Www.proquest.com, 2023, www.proquest.com/wire-feeds/medical-marijuana-market-blooms-with-projected/docview/2859598975/se-2.

Rønne, Sabrina Trappaud, et al. “Physicians’ Experiences, Attitudes, and Beliefs towards Medical Cannabis: A Systematic Literature Review.” BMC Family Practice, vol. 22, no. 1, 21 Oct. 2021, https://doi.org/10.1186/s12875-021-01559-w.

2

Research Paper Outline: The Use of Medical Marijuana in Pain Management

Isairy Otano

Florida National University

Advanced Writing and Research

Professor: Amanda M Giust

January 14, 2024

I. Introduction

A. Background and context of medical marijuana use

B. Statement of the problem: Chronic pain and the need for effective pain management

C. Thesis statement: Exploring the role of medical marijuana in pain alleviation

II. Literature Review

A. Overview of medical marijuana and pain management

B. Key findings from relevant studies

1. Turcotte, D., B.ScPharm PhD. (2023): Cannabis for pain management in older patients

2. Wolfe, D., et al. (2023): Impacts of medical and non-medical cannabis on the health of older adults

3. Galindo-Donaire, J., et al. (2023): The role of personality traits in self-medicated cannabis use for rheumatoid arthritis

4. Eeswara, A., et al. (2023): Effects of non-psychoactive cannabis components on chronic pain

5. Abrams, J., & Ganguli, T. (2022): Celebrities' perspective on cannabis for pain management

6. Gous, N. (2022): Industrial viewpoint on cannabis for pain management trials

7. Neeley, G. W., & Richardson, L. E., Jr. (2023): Cannabis policy adaptation and its impact on pain treatment regulations

III. Medical Marijuana: Mechanisms and Components

A. Cannabinoids and their role in pain relief

B. Specific components such as cannabidiol (CBD) and β-caryophyllene

C. Understanding the interaction with pain receptors

IV. Applications of Medical Marijuana in Pain Management

A. Demographic considerations: Focus on older adults

B. Condition-specific applications: Rheumatoid arthritis as a case study

C. Comparative analysis of therapeutic and non-medical uses

V. Scientific Insights into Cannabis for Pain Treatment

A. Scientific studies on the pharmacological elements of cannabis

B. Case study: Eeswara, A., et al. (2023) - Rat spinal cord injury model

C. Implications for developing targeted pain treatments

VI. Practical Perspectives and Current Trends

A. Celebrities and athletes endorsing medical marijuana for pain relief

B. Industrial perspective: Cannabis company trials for pain management

C. Overview of current state policies on medical marijuana and its adaptability

VII. Conclusion

A. Summary of key findings

B. Implications for the future of pain management

C. Call for further research and policy considerations

Works Cited

Turcotte, D.,B.ScPharm PhD. (2023). Cannabis: Is pain management for older patients going plant-based?  Pharmacy Practice + Business, 10(2), 20-21. https://4x20i0rbt-mp02-y-https-www-proquest-com.proxy.lirn.net/trade-journals/cannabis-is-pain-management-older-patients-going/docview/2792843547/se-2

Wolfe, D., Corace, K., Butler, C., Rice, D., Skidmore, B., Patel, Y., Thayaparan, P., Michaud, A., Hamel, C., Smith, A., Garber, G., Porath, A., Conn, D., Willows, M., Abramovici, H., Thavorn, K., Kanji, S., & Hutton, B. (2023). Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature.  PLoS One, 18(2) https://4x20i0rcf-mp02-y-https-doi-org.proxy.lirn.net/10.1371/journal.pone.0281826

Galindo-Donaire, J., Hernández-Molina, G., Orellana, A. F., Contreras-Yáñez, I., Guaracha-Basáñez, G., Briseño-González, O., & Pascual-Ramos, V. (2023). The role of personality traits on self-medicated cannabis in rheumatoid arthritis patients: A multivariable analysis.  PLoS One, 18(1) https://4x20i0rcn-mp02-y-https-doi-org.proxy.lirn.net/10.1371/journal.pone.0280219

Eeswara, A., Pacheco-Spiewak, A., Jergova, S., & Sagen, J. (2023). Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model.  PLoS One, 18(3) https://4x20i0rcq-mp02-y-https-doi-org.proxy.lirn.net/10.1371/journal.pone.0282920

Abrams, J., & Ganguli, T. (2022, Aug 08). Why pros like brittney griner choose cannabis for their pain.  The New York Times Retrieved from https://4x20i0rcx-mp02-y-https-www-proquest-com.proxy.lirn.net/newspapers/why-pros-like-brittney-griner-choose-cannabis/docview/2700149456/se-2

Gous, N. (2022, Jun 23). East London cannabis firm starts recruiting for pain management trial.  Daily Dispatch  https://4x20i0rd4-mp02-y-https-www-proquest-com.proxy.lirn.net/newspapers/east-london-cannabis-firm-starts-recruiting-pain/docview/2679716186/se-2

Neeley, G. W., & Richardson,Lilliard E.,,Jr. (2023). Cannabis Policy Adaptation: Exploring Frameworks of State Policy Characteristics.  Public Administration Quarterly, 47(3), 253-283. https://4x20i0rdt-mp02-y-https-doi-org.proxy.lirn.net/10.37808/paq.47.3.2

Surname 1

Isairy Otano

Florida National University

Advanced Writing and Research

Professor: Amanda M Giust

January 14, 2024

Pain Management with Medical Marijuana

Medical marijuana for pain relief is a key area of medical research and practice. Alternative remedies have grown as communities struggle to manage chronic pain. According to a research, the worldwide medical marijuana industry is growing exponentially, reaching US$96.7 billion by 2033 (NASDAQ OMX's News Release Distribution Channel, 3). High adoption of medical marijuana, especially for chronic pain management, is driving this rise. Medical marijuana is beneficial because of its chemical constituents, notably THC and CBD from the Cannabis sativa or Cannabis indica plant. Chronic pain, epilepsy, multiple sclerosis, cancer, and psychological disorders have been treated using these substances. Changing regulatory settings, patient and healthcare professional acceptability, and new medical application research drive the global market. This study examines medicinal marijuana's significance in pain therapy, including its expanding acceptance, legislative changes, and opioid use effects.

Medical Marijuana Pain Management Benefits

Medical marijuana has been shown to relieve pain in scientific research and anecdotes. Cannabis and its derivatives help reduce neuropathic, inflammatory, and chronic pain like multiple sclerosis and arthritis, according to emerging research. "Cannabis for the Management of Pain: Balu et al. (5) Pain found cannabis reduced pain more than a placebo. Candeloids may modulate pain, as individuals who used cannabis for pain treatment needed less opioids.

Market Dynamics:

Medical marijuana industry growth is driven by numerous factors, including global regulatory changes. Marijuana legalization and decriminalization have increased worldwide as governments and regulatory agencies recognize its medical benefits. Legalization expands the market and raises public knowledge of medical marijuana as a valid treatment. The widening list of medical disorders for which marijuana can be prescribed has also helped grow the market. Chronic pain, epilepsy, multiple sclerosis, and cancer symptoms have been shown to benefit from marijuana treatment. Product innovation has resulted from large R&D investments due to this acknowledgment (Hall, 6). These inventions include marijuana-based oils, edibles, tinctures, and topicals for distinct patient preferences and medicinal needs. Rising chronic disease rates worldwide drive medical marijuana demand. Medical marijuana can supplement or replace medicines for long-term chronic disease management. This appeals to patients seeking natural or holistic treatments. The market's numerous product offers make medical marijuana accessible and appealing to more patients, boosting its growth and acceptability.

Challenges

However, medical marijuana faces hurdles. Multimarket enterprises struggle with regional regulatory differences. Variability in product availability, legal compliance, and regulatory policies can hinder medicinal marijuana's global progress. The plant's diversity makes quality and standardization of medical marijuana products difficult. Cannabis is a herb with chemical variations, unlike manufactured drugs. Variation in product potency and effectiveness makes it difficult to standardize dose and assure consistent therapeutic benefits for patients.

Social stigma against marijuana usage in several societies remains a barrier. Cannabis is commonly associated with recreational drug use, which has led to social rejection and lack of acceptability in some areas, despite its medicinal benefits. This stigma can effect patient use of medical marijuana and healthcare provider prescriptions. Cannabis' medical research is further hindered by its Schedule I status in several nations, such as the US (Cooper et al., 4). This classification limits research funds and prospects, slowing scientific progress and medicinal advances.

Sectoring the Market:

Product categories, indications, distribution channels, and geographies segment the market. Dried flower and extract products are sold at retail pharmacies and online for pain management and seizure treatment. After many states legalized medical cannabis, the U.S. medical marijuana market, one of the largest worldwide, evolved. Strong research, product innovation, and a strong supply network boost its growth. Due to changing regulations and growing acceptance of cannabis-based medicines, the market is likely to rise. Tilray, Aurora Cannabis, Canopy Growth Corporation, and others are strengthening their positions through collaborations, acquisitions, and product line extensions. Canopy Growth's acquisition of Supreme Cannabis Company and Tauriga Sciences' cannabis/CBD chewing gum production agreement demonstrate the market's volatility.

Legal and Moral Issues

Medical marijuana is still debated in many places. Ethical issues like equitable access, patient autonomy, and cannabis stigma also influence its usage in pain therapy. Rønne et al. (5) reviewed cannabis prescribing ethics, including the necessity to weigh benefits and dangers. The changing legal landscape necessitates consistent norms and recommendations for safe and effective use.

Conclusion

Medical marijuana pain management is a promising topic that is expanding quickly. Medical marijuana's expanding global industry due to changing rules, acceptance, and research shows its growing importance in healthcare. Studies sheds light on how medical cannabis certification affects opioid consumption, supporting its use in pain therapy. As the industry grows, more research and clinical trials are needed to understand medical marijuana's function in chronic pain therapy and its problems.

Works Cited

Balu, Alan, et al. “Medical Cannabis Certification Is Associated with Decreased Opiate Use in Patients with Chronic Pain: A Retrospective Cohort Study in Delaware.” Cureus, 7 Dec. 2021, https://doi.org/10.7759/cureus.20240.

Cooper, Ziva D, et al. “Challenges for Clinical Cannabis and Cannabinoid Research in the United States.” JNCI Monographs, vol. 2021, no. 58, 27 Nov. 2021, pp. 114–122, https://doi.org/10.1093/jncimonographs/lgab009.

Hall, Wayne. “The Costs and Benefits of Cannabis Control Policies.” Dialogues in Clinical Neuroscience, vol. 22, no. 3, Sept. 2020, pp. 281–287, www.ncbi.nlm.nih.gov/pmc/articles/PMC7605025/, https://doi.org/10.31887/dcns.2020.22.3/whall.

NASDAQ OMX’s News Release Distribution Channel. “Medical Marijuana Market Blooms with a Projected Value of US$96.7 Billion by 2033, Persistence Market Research.” Www.proquest.com, 2023, www.proquest.com/wire-feeds/medical-marijuana-market-blooms-with-projected/docview/2859598975/se-2.

Rønne, Sabrina Trappaud, et al. “Physicians’ Experiences, Attitudes, and Beliefs towards Medical Cannabis: A Systematic Literature Review.” BMC Family Practice, vol. 22, no. 1, 21 Oct. 2021, https://doi.org/10.1186/s12875-021-01559-w.